Spark Therapeutics, Inc. (NASDAQ:ONCE) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday.
A number of other research firms also recently weighed in on ONCE. Royal Bank Of Canada restated a “buy” rating on shares of Spark Therapeutics in a research report on Wednesday, October 25th. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. Raymond James Financial, Inc. started coverage on Spark Therapeutics in a research report on Thursday, October 12th. They issued an “outperform” rating and a $96.00 target price for the company. Chardan Capital upgraded Spark Therapeutics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $60.00 to $100.00 in a research report on Tuesday, August 8th. Finally, BidaskClub upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $90.36.
Spark Therapeutics (NASDAQ ONCE) opened at $72.65 on Tuesday. Spark Therapeutics has a fifty-two week low of $47.03 and a fifty-two week high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same period last year, the company earned ($1.07) earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. equities research analysts anticipate that Spark Therapeutics will post -7.62 EPS for the current fiscal year.
In other news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the company’s stock in a transaction on Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the transaction, the director now directly owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $71.44, for a total transaction of $392,920.00. Following the completion of the transaction, the insider now directly owns 8,146 shares in the company, valued at $581,950.24. The disclosure for this sale can be found here. Insiders sold 1,099,659 shares of company stock worth $92,457,658 over the last ninety days. 7.30% of the stock is currently owned by company insiders.
A number of institutional investors have recently bought and sold shares of ONCE. Ameritas Investment Partners Inc. increased its position in Spark Therapeutics by 23.6% during the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock worth $122,000 after buying an additional 389 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in Spark Therapeutics during the second quarter worth $143,000. BNP Paribas Arbitrage SA increased its position in Spark Therapeutics by 530.1% during the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the last quarter. Pacad Investment Ltd. increased its position in Spark Therapeutics by 75.0% during the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock worth $209,000 after buying an additional 1,500 shares during the last quarter. Finally, Teacher Retirement System of Texas acquired a new position in Spark Therapeutics during the third quarter worth $225,000. 77.94% of the stock is currently owned by hedge funds and other institutional investors.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.